A multicentre, prospective phase 2 study of weekly schedule of carboplatin (C) plus paclitaxel (P) in first-line treatment of elderly patients (pts) with ovarian cancer (OC). The MITO (Multicentre Italian Trials in Ovarian cancer)-5 study
Vittorina Zagonel(Istituto Oncologico Veneto), Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanna Cavazzini(University of Padua), Gabriella Ferrandina(Agostino Gemelli University Polyclinic), Marco Di Maio(Università Cattolica del Sacro Cuore), Rocco De Vivo(Università Cattolica del Sacro Cuore), D. Natale(Università Cattolica del Sacro Cuore), Antonietta Fabbrocini, A. De Matteis(Università Cattolica del Sacro Cuore), Paolo Scollo(Ospedale Cannizzaro)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k